Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P01178 (
oxytocin
)
15,767
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
In this investigation, the
Oxytocin
(OT) and 13, 14-
Dihydro
-15 Keto PGF 2-alpha (PGFM) levels were investigated in patients who required ripening of the cervix prior to induction of labour. Under randomized conditions four PGE2-Gel-groups and 1 Placebo group was formed. The patients who received PGE2-Gel were treated either with .4 mg PGE2-Gel intercervically without prior treatment with Betamimetica (n = 6) or 30 minutes prior to the application of .4 mg PGE2-Gel intercervically with 5 mb Fenoterol (n = 6) or 10 mg Ritadrine (n = 6) or 20 micrograms Clenbuterol (n = 6). These drugs were given by mouth. A control group of 6 patients received Gel without PGE2 Placebo. In previous investigations, it was shown that the
Oxytocin
level rises following the intercervical administration of PGE2-Gel to an unripe cervix whereas the PGFM level remains unchanged. Oral administration of Fenoterol inhibited the PG induced rise of the
Oxytocin
level and kept the
Oxytocin
level in the same range as following the administration of a Placebo. The present investigation served to check whether Ritadrine and Clenbuterol had an
Oxytocin
inhibiting effect as well as Fenoterol. It was found that administration of Betamimetica did not inhibit the ripening effect of PGE2-Gel on the cervix. Although labour did not start in 12 of 18 women treated with Betamimetica during four hours, the cervix ripened in the same manner as in women with labour. The administration of Placebo instead of PGE2-Gel showed no ripening effect (P less than 00001). Following the administration of Fenoterol the maternal heart rate increases significantly compared to Placebo.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:[Influence of fenoterol, ritodrine and clenbuterol on maternal oxytocin and PGFM levels]. 655 19
13 ,14 -
Dihydro
-15-keto-PGF2 alpha (PGFM) serum levels were determined by radioimmunoassay in 101 postpartum women who were treated with 200 micrograms methergin, 5 I.U.
oxytocin
and 500 micrograms sulprostone, respectively, 30 min after expulsion of placenta. All patients had normal deliveries. The present radioimmunoassay system did not show cross-reactivity with sulprostone. In addition, radioimmunoassayable sulprostone serum levels were monitored. Covariance analysis of area under PGFM serum levels between time zero and 180 min after application of oxytocics was performed. A higher but statistically not significantly PGFM serum level was maintained in subjects treated with sulprostone. Sulprostone serum levels are rapidly attained after application. Decrease of radioimmunoassayable sulprostone indicates a half-life of 75 min. These data corroborate clinical findings of an accompanying paper and combine to suggest that sulprostone may be a useful alternative therapy in high-risk patients with severe postpartum atony and hemorrhage in whom prior preventive measures have failed.
...
PMID:13,14-Dihydro-15-keto-PGF2 alpha (PGFM) and sulprostone serum levels after application of sulprostone to postpartum women. 668 61